Pharmaceutical Executive
The last thing on the mind of an adventurous traveler is a pre-trip immunization, which, consequently, is not top-of-mind for their healthcare providers, either.
POSTCARDS
ICC
BRAND TravelWise Program CLIENT Sanofi Pasteur AT RIGHT: Chet Moss, executive vice president, chief creative officer NOT PICTURED: Karen Neale, writer; Suzanne Elward, art director
The last thing on the mind of an adventurous traveler is a pre-trip immunization, which, consequently, is not top-of-mind for their healthcare providers, either. The work of ICC for Sanofi Pasteur helped deepen the necessary dialogue and increase awareness of the need for vaccination when traveling to many far-off lands through the use of classic souvenir postcards from more than 50 years ago.
The campaign embraced multiple tactics all predicated on the visual parody of the postcards. "The marketing challenge was to get people to pay attention to these insidious diseases lurking in foreign lands, and to ramp up the discussion between healthcare provider and traveler," notes Chet Moss, executive vice president, chief creative officer of ICC. "It was done in a warm and approachable way."
Each card was driven by the same call to action: "Be Aware...Prepare!" Yet each advertisement features a surprising twist. For instance, expecting to see Yellowstone National Park on the postcard, the airbrushed message reveals another possible destination: Yellow Fever. "You can't help but pay attention," says Moss. "You take common ground and put a twist on it...and that's what great advertising is about."
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.